Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of obinutuzumab (RG7159) in CD20-positive B-cell non-Hodgkin lymphoma
jRCT2080221745Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Mar 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of obinutuzumab in non-Hodgkin lymphoma (NHL), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Safety and tolerability of obinutuzumab. Started Mar 2012; status: completed.
02
Drugs
obinutuzumab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on jRCT2080221745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221745.